Pliant Cash And Short Term Investments vs Total Liab Analysis

PLRX Stock

USD 13.53 0.19 1.42%

Pliant Therapeutics financial indicator trend analysis is much more than just breaking down Pliant Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pliant Therapeutics is a good investment. Please check the relationship between Pliant Therapeutics Cash And Short Term Investments and its Total Liab accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pliant Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pliant Stock please use our How to Invest in Pliant Therapeutics guide.

Cash And Short Term Investments vs Total Liab

Cash And Short Term Investments vs Total Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pliant Therapeutics Cash And Short Term Investments account and Total Liab. At this time, the significance of the direction appears to have weak relationship.

The correlation between Pliant Therapeutics' Cash And Short Term Investments and Total Liab is 0.3. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Total Liab in the same time period over historical financial statements of Pliant Therapeutics, assuming nothing else is changed. The correlation between historical values of Pliant Therapeutics' Cash And Short Term Investments and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of Pliant Therapeutics are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Cash And Short Term Investments i.e., Pliant Therapeutics' Cash And Short Term Investments and Total Liab go up and down completely randomly.

Correlation Coefficient

0.3

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Pliant Therapeutics balance sheet. This account contains Pliant Therapeutics investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Pliant Therapeutics fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Most indicators from Pliant Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pliant Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pliant Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Pliant Stock please use our How to Invest in Pliant Therapeutics guide.At this time, Pliant Therapeutics' Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value is likely to rise to about 1.1 B in 2024, whereas Selling General Administrative is likely to drop slightly above 29.4 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Income	272K	4.7M	20.5M	21.5M
Net Interest Income	272K	3.9M	19.2M	20.2M

Interest Income Net Interest Income

Pliant Therapeutics fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Net Receivables	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Other Current Liab	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets
Total Assets		0.9	0.99	0.78	0.95	-0.96	0.69	0.66	1.0	0.53	0.31	1.0	0.89	0.6	0.76	0.92	0.5	0.47	0.6	0.3	-0.26	0.98	0.93	-0.76	0.38	0.9
Total Current Liabilities	0.9		0.88	0.79	0.89	-0.91	0.72	0.61	0.89	0.39	0.31	0.9	0.98	0.66	0.92	0.99	0.63	0.62	0.71	0.31	-0.19	0.91	0.95	-0.73	0.61	0.97
Total Stockholder Equity	0.99	0.88		0.69	0.98	-0.95	0.69	0.54	0.99	0.46	0.14	0.99	0.9	0.57	0.76	0.91	0.51	0.54	0.56	0.17	-0.39	0.99	0.89	-0.84	0.38	0.9
Other Liab	0.78	0.79	0.69		0.68	-0.68	0.59	0.94	0.77	0.69	0.7	0.77	0.71	0.76	0.6	0.78	0.49	0.3	0.64	0.5	0.19	0.68	0.84	-0.5	0.46	0.8
Net Tangible Assets	0.95	0.89	0.98	0.68		-0.91	0.63	0.49	0.95	0.47	0.07	0.95	0.92	0.6	0.79	0.9	0.59	0.66	0.61	0.07	-0.41	0.97	0.87	-0.9	0.49	0.93
Retained Earnings	-0.96	-0.91	-0.95	-0.68	-0.91		-0.74	-0.56	-0.96	-0.31	-0.26	-0.96	-0.9	-0.57	-0.84	-0.92	-0.54	-0.51	-0.63	-0.28	0.33	-0.98	-0.9	0.72	-0.43	-0.89
Accounts Payable	0.69	0.72	0.69	0.59	0.63	-0.74		0.51	0.69	0.13	0.14	0.69	0.71	0.6	0.52	0.68	0.26	0.25	0.34	0.23	-0.39	0.66	0.69	-0.62	0.26	0.69
Cash	0.66	0.61	0.54	0.94	0.49	-0.56	0.51		0.65	0.72	0.85	0.66	0.49	0.67	0.37	0.61	0.28	-0.03	0.5	0.69	0.4	0.51	0.73	-0.25	0.24	0.61
Cash And Short Term Investments	1.0	0.89	0.99	0.77	0.95	-0.96	0.69	0.65		0.52	0.3	1.0	0.89	0.59	0.76	0.92	0.49	0.47	0.59	0.29	-0.27	0.98	0.92	-0.76	0.37	0.9
Net Receivables	0.53	0.39	0.46	0.69	0.47	-0.31	0.13	0.72	0.52		0.52	0.53	0.36	0.37	0.1	0.45	0.06	-0.08	0.23	0.53	0.41	0.38	0.6	-0.27	0.0	0.46
Total Liab	0.31	0.31	0.14	0.7	0.07	-0.26	0.14	0.85	0.3	0.52		0.3	0.16	0.35	0.18	0.32	0.08	-0.28	0.34	0.8	0.7	0.17	0.44	0.24	0.08	0.24
Total Current Assets	1.0	0.9	0.99	0.77	0.95	-0.96	0.69	0.66	1.0	0.53	0.3		0.89	0.59	0.76	0.92	0.49	0.47	0.59	0.29	-0.26	0.98	0.93	-0.76	0.37	0.9
Common Stock	0.89	0.98	0.9	0.71	0.92	-0.9	0.71	0.49	0.89	0.36	0.16	0.89		0.56	0.91	0.98	0.57	0.68	0.61	0.18	-0.34	0.92	0.92	-0.79	0.54	0.95
Property Plant Equipment	0.6	0.66	0.57	0.76	0.6	-0.57	0.6	0.67	0.59	0.37	0.35	0.59	0.56		0.54	0.59	0.79	0.37	0.85	0.25	0.06	0.56	0.64	-0.61	0.77	0.76
Short Long Term Debt Total	0.76	0.92	0.76	0.6	0.79	-0.84	0.52	0.37	0.76	0.1	0.18	0.76	0.91	0.54		0.89	0.75	0.78	0.77	0.11	-0.28	0.85	0.78	-0.66	0.73	0.87
Other Current Liab	0.92	0.99	0.91	0.78	0.9	-0.92	0.68	0.61	0.92	0.45	0.32	0.92	0.98	0.59	0.89		0.56	0.58	0.66	0.35	-0.18	0.93	0.97	-0.71	0.52	0.96
Property Plant And Equipment Net	0.5	0.63	0.51	0.49	0.59	-0.54	0.26	0.28	0.49	0.06	0.08	0.49	0.57	0.79	0.75	0.56		0.73	0.95	-0.09	-0.12	0.58	0.48	-0.62	0.97	0.71
Net Debt	0.47	0.62	0.54	0.3	0.66	-0.51	0.25	-0.03	0.47	-0.08	-0.28	0.47	0.68	0.37	0.78	0.58	0.73		0.55	-0.49	-0.58	0.61	0.39	-0.77	0.72	0.64
Non Current Assets Total	0.6	0.71	0.56	0.64	0.61	-0.63	0.34	0.5	0.59	0.23	0.34	0.59	0.61	0.85	0.77	0.66	0.95	0.55		0.23	0.1	0.63	0.64	-0.53	0.92	0.78
Non Currrent Assets Other	0.3	0.31	0.17	0.5	0.07	-0.28	0.23	0.69	0.29	0.53	0.8	0.29	0.18	0.25	0.11	0.35	-0.09	-0.49	0.23		0.73	0.16	0.52	0.29	-0.07	0.25
Other Assets	-0.26	-0.19	-0.39	0.19	-0.41	0.33	-0.39	0.4	-0.27	0.41	0.7	-0.26	-0.34	0.06	-0.28	-0.18	-0.12	-0.58	0.1	0.73		-0.38	-0.02	0.63	-0.05	-0.2
Common Stock Total Equity	0.98	0.91	0.99	0.68	0.97	-0.98	0.66	0.51	0.98	0.38	0.17	0.98	0.92	0.56	0.85	0.93	0.58	0.61	0.63	0.16	-0.38		0.89	-0.81	0.46	0.91
Common Stock Shares Outstanding	0.93	0.95	0.89	0.84	0.87	-0.9	0.69	0.73	0.92	0.6	0.44	0.93	0.92	0.64	0.78	0.97	0.48	0.39	0.64	0.52	-0.02	0.89		-0.63	0.44	0.94
Non Current Liabilities Total	-0.76	-0.73	-0.84	-0.5	-0.9	0.72	-0.62	-0.25	-0.76	-0.27	0.24	-0.76	-0.79	-0.61	-0.66	-0.71	-0.62	-0.77	-0.53	0.29	0.63	-0.81	-0.63		-0.55	-0.82
Capital Lease Obligations	0.38	0.61	0.38	0.46	0.49	-0.43	0.26	0.24	0.37	0.0	0.08	0.37	0.54	0.77	0.73	0.52	0.97	0.72	0.92	-0.07	-0.05	0.46	0.44	-0.55		0.68
Other Current Assets	0.9	0.97	0.9	0.8	0.93	-0.89	0.69	0.61	0.9	0.46	0.24	0.9	0.95	0.76	0.87	0.96	0.71	0.64	0.78	0.25	-0.2	0.91	0.94	-0.82	0.68

Click cells to compare fundamentals

Pliant Therapeutics Account Relationship Matchups

Pliant Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	119.1M	295.5M	221.2M	350.6M	512.2M	537.8M
Total Current Liabilities	8.2M	11.6M	16.8M	23.9M	28.5M	15.3M
Total Stockholder Equity	(435K)	283.1M	199.1M	313.3M	473.6M	497.3M
Net Tangible Assets	(76.3M)	283.1M	199.1M	313.3M	360.3M	378.4M
Retained Earnings	(76.3M)	(117.8M)	(215.1M)	(338.4M)	(499.7M)	(474.8M)
Accounts Payable	1.3M	2.0M	3.0M	1.6M	4.5M	2.6M
Cash	85.8M	50.9M	51.7M	33.7M	63.2M	55.1M
Cash And Short Term Investments	102.8M	276.9M	200.6M	331.2M	494.2M	519.0M
Net Receivables	7.4M	9.4M	2.0M	2.0M	3.0M	3.8M
Total Liab	119.5M	12.5M	22.2M	37.3M	38.6M	34.4M
Total Current Assets	111.9M	290.8M	209.4M	340.3M	505.5M	530.8M
Property Plant Equipment	4.1M	4.3M	10.9M	4.5M	5.2M	5.5M
Short Long Term Debt Total	444K	283K	7.2M	15.8M	11.4M	6.5M
Other Current Liab	6.9M	9.6M	10.1M	17.4M	21.4M	12.4M
Property Plant And Equipment Net	4.1M	4.3M	10.9M	9.9M	4.8M	7.0M
Net Debt	(85.4M)	(50.6M)	(44.5M)	(17.9M)	(51.9M)	(54.5M)
Non Current Assets Total	7.2M	4.8M	11.8M	10.3M	6.7M	8.3M
Non Currrent Assets Other	3.1M	451K	838K	394K	1.9M	957.1K
Other Assets	3.1M	451K	838K	394K	1.0	0.95
Common Stock Shares Outstanding	35.6M	35.6M	35.8M	42.0M	58.7M	41.1M
Short Term Investments	17.0M	226.0M	148.9M	297.5M	431.0M	452.6M
Liabilities And Stockholders Equity	119.1M	295.5M	221.2M	350.6M	512.2M	286.9M
Non Current Liabilities Total	111.3M	866K	5.3M	13.4M	10.1M	9.6M
Capital Lease Obligations	444K	283K	7.2M	5.9M	1.3M	1.3M
Other Current Assets	1.7M	4.5M	6.8M	7.1M	8.3M	5.3M
Other Stockholder Equity	2.2M	400.9M	414.3M	653.7M	973.0M	1.0B
Net Invested Capital	(76.3M)	283.1M	199.1M	323.3M	483.6M	507.8M
Accumulated Other Comprehensive Income	(1K)	(32K)	(201K)	(2.0M)	345K	362.3K
Non Current Liabilities Other	10K	2K	5.3M	3.4M	3.9M	4.1M
Net Working Capital	103.7M	279.2M	192.6M	316.4M	477.0M	261.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Pliant Stock Analysis

When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pliant Cash And Short Term Investments vs Total Liab Analysis

Cash And Short Term Investments vs Total Liab

Cash And Short Term Investments vs Total Liab Correlation Analysis

Correlation Coefficient

Cash And Short Term Investments

Total Liab

Pliant Therapeutics fundamental ratios Correlations

Pliant Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pliant Therapeutics fundamental ratios Accounts

Also Currently Popular

Additional Tools for Pliant Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Other Current Liab	+ 0.99	Total Current Liabilities
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity

Common Stock Total Equity	- 0.98	Retained Earnings
Total Current Assets	- 0.96	Retained Earnings
Cash And Short Term Investments	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Total Assets
Retained Earnings	- 0.95	Total Stockholder Equity
Other Current Liab	- 0.92	Retained Earnings